RWE: Austria
Efficacy
PFS
ORR
60%
CR
48%
AT LAST FOLLOW UP
61%
ALIVE, CR
16%
ALIVE, ACTIVE DISEASE
| Safety | |
|---|---|
| CRSGrade ≥3 | 0% |
| ICANSGrade ≥3 | 3% |
Limitations: include small population and short median follow-up period of 4.85 months
- Reference: 1. Rudzki JD et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Poster 2964.
Data collection
Sep 2019–Oct 2022
Austrian CAR-T Network
(6 centers)
Median follow-up
months
No. of patients infused with tisa-cel
| Median age (range) years | 61 (30–83)29% |
| Gender (male) | NR |
| ECOG ≥2 | 0% |
| IPI >3 | 19%* |
| HG lymphoma(double or triple hit) | 20%NR |
| DLBCL | 77% |
| Transformed lymphoma | NR |
| Comorbidities | NR |
| LDH elevated (>500 U/l) | 3%† |
| Prior therapies, median≥3 lines | NR55% |
| Primary refractoryRefractory to last lineRelapsed | NRNRNR |
| Prior SCTAllo | 33%NR |
| Bridging therapy | 93% |
| Median time to infusion | NR |
Patients were selected for CAR‑T therapy based on comorbidities and fitness status using an algorithm
- *Estimated, data missing for 11 patients. †Estimated, data missing for 1 patient.
- Reference: 1. Rudzki JD et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Poster 2964.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete